2020 Southwest Prostate Cancer Symposium 

Virtual CME Symposium

December 12, 2020 – 8:00am-5:30pm (EST)

innovations in urologic practice logo

A Must Attend Event!

The 2020 Virtual Southwest Prostate Cancer Symposium (SPCS 2020) is intended for urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. It will educate the attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices.

The goal of this educational program is to equip urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in prostate cancer care with the up-to-date clinical knowledge and tools they need to best treat their patients. The program aims to provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.

Program Co-Chair

Nelson N. Stone, MD

Professor of Urology and Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Program Co-Chair

Richard G. Stock, MD

Professor of Radiation Oncology
Director of Genito-Urinary Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Attend Lectures and Panel Discussions

Watch Experts Discuss and Demonstrate Urologic Procedures

Connect with peers and experts

How the Virtual CME Symposia Works

The virtual, Zoom-based event is open to all Grand Rounds in Urology members and the larger urology community.


The virtual 2020 Southwest Prostate Cancer Symposium offers a robust online program with two multi-track sessions, including CME lectures, panels virtual hands-on training demonstrations,networking and more. Join us for the full virtual conference broadcast on Saturday, December 12, 2020, from 8:00am-5:30pm (EST).

Saturday, December 12, 2020



Welcome and Introduction
Program Co-Chairs: Nelson N. Stone, MD, and Richard G. Stock, MD


SESSION 1 – Identifying Candidates for Focal Therapy


Pathologist’s Perspective
M. Scott Lucia, MD   


Transrectal mpMRI Fusion Biopsy
Leonard S. Marks, MD


Freehand Transperineal Prostate Biopsy Under Local Anesthesia
Michael A. Gorin, MD


Can One Biopsy Event Identify Focal Therapy Candidates?
Nelson N. Stone, MD


Application of MRI Fusion Biopsy Results to Focal Therapy
Leonard S. Marks, MD


Panel Discussion
Moderator: Nelson N. Stone, MD


Exhibits and Networking


SESSION 2 – Limiting Radiation Injury


Does Anatomic Rectal Displacement Improve Dosimetry and Reduce Injury?
Jon S. Prescott, MD


Radiation Dose Requirements for Local Disease Eradication
Nelson N. Stone, MD


Brachytherapy and Focal Therapy Outcomes
Richard G. Stock, MD


Panel Discussion
Moderator: Richard G. Stock, MD


Spotlight Product Theaters


Spotlight Product Theater 1
Important Evidence-Based Changes in the Metastatic
Castration-Sensitive Prostate Cancer Treatment Landscape
Speaker: Edward M. Uchio, MD, FACS, CPI
Sponsored by Astellas Pharma US and Pfizer Oncology


Spotlight Product Theater 2
Erleada: TITAN and New Data for SPARTAN Final Analysis
Speaker: Matthew B. Rettig, MD
Supported by Janssen Biotech


Spotlight Product Theater 3
An Innovative Abiraterone Acetate, YONSA®
Speaker: Raoul S. Concepcion, MD
Sponsored by Sun Pharma


SESSION 3 – Virtual Hands-on Training


Office-Based and Transperineal mpMRI Fusion Biopsy
Michael A. Gorin, MD


Transrectal mpMRI Fusion Biopsy
Leonard Marks, MD


Transperineal Hydrogel Placement
Jon S. Prescott, MD


Brachytherapy Focal Therapy Technique
Richard G. Stock and Nelson N. Stone


Panel Discussion and Closing Remarks
Nelson N. Stone, MD

Invited Faculty


Nelson N. Stone, MD

Professor of Urology and Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York


Richard G. Stock, MD

Professor of Radiation Oncology
Director of Genito-Urinary Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Michael A. Gorin, MD

Urology Associates & UPMC Western Maryland
Cumberland, Maryland

M. Scott Lucia, MD

Vice Chair of the Department of Pathology
Director of Anatomic Pathology​
Director of the Prostate Diagnostic Laboratory
University of Colorado, Denver
Aurora, Colorado

Leonard S. Marks, MD

Professor and DeKernion Endowed Chair in Urology
UCLA Medical Center
Los Angeles, California

Jon S. Prescott, MD

Medical Director
Northern Ohio Regional Cancer Center
Brook Park, Ohio

CME Information

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical College of Wisconsin (MCW) and Carden Jennings Publishing Co., Ltd. (CJP). The Medical College of Wisconsin (MCW)  is accredited by ACCME to provide continuing medical education for physicians.

MCW designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is designed for radiation oncologists, urologists, medical oncologists, primary care specialists, and other healthcare professionals involved in the diagnosis and management of prostate cancer.

At the conclusion of the activity, participants should be able to:

  • Assess which diagnostic tests help distinguish a lower versus higher-risk patient
  • Recognize how the decrease in early detection has resulted in prostate cancers presenting at a more advanced stage
  • Describe technical advances, including robotic radical prostatectomy, image-guided external beam radiotherapy (IGRT), proton beam therapy, hypofractionated radiotherapy (SBRT), computer-guided brachytherapy, and mpMRI, and demonstrate their role in prostate cancer treatment and detection
  • Identify appropriate patients for radiation-based treatments such as brachytherapy, brachytherapy boost, IMRT/IGRT, proton therapy robotic and open prostatectomy, and focal therapy taking serum and genetic influences into account
  • Assess the implications of local failure after radiation therapy and introduce new radio-protective technologies
  • Discuss treatment of advanced disease, specifically in the non-metastatic CRPC disease state
  • Contribute to group discussions regarding potential future research directions to address how we can improve inter-observer agreement and overall quality, develop machine-learning techniques, and improve current technology for staging high-risk disease and for disease monitoring after therapy.

Lectures | Debates | Question and Answer Sessions | Panel Discussions | Live Surgical Case Demonstrations

Evaluation by questionnaire will address program content, presentation, and possible bias.

Support Opportunities

To inquire about support opportunities, please contact:

Marc Weathersby, Chief Marketing Officer
Tel:434-817-2000, x193    Cell: 434-989-5508
Fax 434-817-2020    mweathersby@cjp.com

Exhibit and Sponsor Prospectus


During these times, Grand Rounds in Urology and the Southwest Prostate Cancer Symposium are committed to you and helping your practice run as best as it can.



Astellas Pharma US and Pfizer Oncology   •    Janssen Biotech


Sun Pharma


Accuray   •   Bayer   •   Blue Earth Diagnostics
Boston Scientific   •   Foundation Medicine   •   Hitachi Healthcare
IsoAid   •   IsoRay   •   Koelis   •   Perineologic
Progenics Pharmaceutical/Lantheus Holdings


Accuray   •    American Brachytherapy Society
Astellas Pharma US and Pfizer Oncology
Bayer   •    Blue Earth Diagnostics  •    Boston Scientific
Foundation Medicine   •    Hitachi Healthcare
IsoAid   •    IsoRay   •    Janssen Biotech   •    Koelis
Perineologic   •    Progenics Pharmaceutical/Lantheus Holdings  •    Sun Pharma


Have Questions? Contact Us.